Company intelligence / Profile preview
Canary Cure Therapeutics
New York, NY, USAcanarycure.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Canary Cure’s lead candidate, CCT‑217, is a first-in-class dual siRNA therapy targeting CB1R and ZFP423 for obesity. Preclinical results show significant weight loss with preservation of lean body mass and potential for single or twice-yearly dosing. The company plans to submit an IND in Q3 2025 and begin Phase 1 clinical trials in 2026.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- RNA interference (RNAi)siRNA therapeuticsmicroRNA diagnostics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Not publicly disclosed as of May/June 2025
Beyond the preview
Go deeper on Canary Cure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canary Cure Therapeutics.